Fundamental Analysis of ACASTI PHARMA INC(NASDAQ:ACST) stock

Fundamental Rating

ACST gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. While ACST has a great health rating, there are worries on its profitability. ACST is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ACST has reported negative net income.

In the past year ACST has reported a negative cash flow from operations.

ACST had negative earnings in each of the past 5 years.

ACST had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ACST has a Return On Assets of -50.89%. This is comparable to the rest of the industry: ACST outperforms 42.56% of its industry peers.

ACST has a Return On Equity of -59.94%. This is comparable to the rest of the industry: ACST outperforms 53.33% of its industry peers.

		Industry Rank	Sector Rank
ROA	-50.89%
ROE	-59.94%
ROIC	N/A

ROA(3y)-30.92%

ROA(5y)-62.17%

ROE(3y)-35.6%

ROE(5y)-132.19%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ACST does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ACST has about the same amout of shares outstanding than it did 1 year ago.

The number of shares outstanding for ACST has been increased compared to 5 years ago.

There is no outstanding debt for ACST. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ACST has an Altman-Z score of -2.54. This is a bad value and indicates that ACST is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -2.54, ACST is in line with its industry, outperforming 44.62% of the companies in the same industry.

ACST has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-2.54

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

ACST has a Current Ratio of 15.19. This indicates that ACST is financially healthy and has no problem in meeting its short term obligations.

ACST's Current ratio of 15.19 is amongst the best of the industry. ACST outperforms 92.31% of its industry peers.

ACST has a Quick Ratio of 15.19. This indicates that ACST is financially healthy and has no problem in meeting its short term obligations.

The Quick ratio of ACST (15.19) is better than 92.31% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	15.19
Quick Ratio	15.19

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ACST shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -108.14%.

EPS 1Y (TTM)-108.14%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q44.63%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, ACST will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.36% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y26.59%

EPS Next 2Y19.48%

EPS Next 3Y13.93%

EPS Next 5Y17.36%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ACST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ACST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ACST's earnings are expected to grow with 13.93% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y19.48%

EPS Next 3Y13.93%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ACST!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ACASTI PHARMA INC

NASDAQ:ACST (4/23/2024, 7:00:00 PM)

2.88

+0.03 (+1.05%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap27.07M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-50.89%
ROE	-59.94%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	15.19
Quick Ratio	15.19
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-108.14%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y26.59%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ACASTI PHARMA INC (ACST)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens